Procept biorobotics corporation (procept) became aware that an 85-year-old male patient with an approximately 300-cc prostate size and known cancer underwent an aquablation procedure for symptomatic benign prostatic hyperplasia (bph).The aquablation procedure was completed without complications and the foley balloon catheter was clear when the patient left the operating room (or).Post aquablation procedure, the patient experienced gastrointestinal (gi) problems at which point a ct scan was performed and found no anomalies.The patient's gi problems were resolved and was discharged home.Seven (7) days post-aquablation procedure, the patient had an emergency call and passed away on the way to the emergency room.Through a follow-up conversation with the treating physician, procept confirmed that the patient began vomiting blood leading to the patient coding a week after the aquablation procedure.Per the information obtained through the treating physician, the autopsy report listed the primary cause of death as an undiagnosed chronic esophageal ulcer.The treating physician confirmed that the event was unrelated to the aquablation procedure or a malfunction of the aquabeam robotic system.
|
H.10 additional manufacturer narrative: the aquabeam robotic system was returned for investigation as it remains in use at the user facility.The investigation consisted of the information obtained through a conversation with the treating surgeon, plus review of the treatment log files, device history record (dhr), and labeling.The aquabeam robotic system's treatment log file was reviewed, which confirmed no malfunctions during the aquablation procedure.The review of the treatment log file indicated that the system functioned as designed.A review of the device history record (dhr) for aquabeam robotic system ab2000-b rev d/serial number (b)(6) was performed, which confirmed that there were no nonconformances, failures, discrepancies, or missed steps during the manufacturing process that could be related to the reported event.The review indicated that the system and its associated component met all design and manufacturing specifications when released for distribution.The aquabeam robotic system instructions for use (ifu), ifu0101-00, rev.E, was reviewed and states the following: 3.Contraindications.Do not use the aquabeam robotic system in patients who do not meet the indication for the system's intended use.Investigation of the treatment log files, device history record, labeling/ifu, and information received through the treating surgeon confirmed that no device malfunction occurred and the aquabeam robotic system functioned as intended and was used in accordance with its instructions for use.The reported event was determined not to be device-related.Submission of this report does not constitute an admission that the manufacturer's product caused or contributed to the event.
|